Persistence of chronic inflammation after regular blood transfusion therapy in sickle cell anemia
Blood Adv
.
2023 Feb 14;7(3):309-313.
doi: 10.1182/bloodadvances.2022007464.
Authors
Abdoul Karim Dembélé
1
2
3
,
Patricia Hermand
1
3
,
Florence Missud
4
,
Emmanuelle Lesprit
5
,
Laurent Holvoet
4
,
Valentine Brousse
1
3
4
,
Ghislaine Ithier
4
,
Marie-Helene Odievre
1
3
6
,
Malika Benkerrou
4
7
,
Caroline Le Van Kim
1
3
,
Berengere Koehl
1
3
4
Affiliations
1
UMR_S1134, BIGR, Inserm, Université de Paris, Paris, France.
2
Centre de Recherche et de Lutte Contre la Drépanocytose, Bamako, Mali.
3
Laboratoire d'Excellence du Globule Rouge, Imagine Institute, Paris, France.
4
Sickle Cell Disease Center, Hematology Unit, Robert Debré Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
5
Etablissement Français du Sang, Paris, France.
6
Sickle Cell Disease Center, General Pediatric Unit, Trousseau Hospital, AP-HP, Paris, France.
7
UMR_S1123, ECEVE, Inserm, Université de Paris, Paris, France.
PMID:
35834752
PMCID:
PMC9898595
DOI:
10.1182/bloodadvances.2022007464
No abstract available
Publication types
Research Support, Non-U.S. Gov't
MeSH terms
Anemia, Sickle Cell* / complications
Anemia, Sickle Cell* / therapy
Blood Transfusion
Humans
Inflammation / etiology